1. Bayer to buy AskBio for $2B in bid to become gene therapy player — Novartis' most advanced kidney compound shows promise in C3G — JNJ and AZ COVID vaccine trials resuming — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice


Discussion in 'Ask Dr. Dave' started by Anonymous, Apr 9, 2014 at 11:28 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Opinion now please?

    from: the 5 dollar guy

  2. DrDave

    DrDave Member

    May 6, 2006
    Likes Received:
    Hey, good to hear from you!

    Unfortunately I think our original Actos exchange was deleted during a CP cleanup. In a nutshell, I will say in 2014 my feeling is that pioglitazone has a very limited role. Metformin, GLP-1s, DPP4s and probably SGLT-2 inhibitors are better choices. but, in a patient WITHOUT CHF concerns, it's probably safer than sulfonyureas.

    How about you?